

Date 23.12.90

Attachment 1.
(FACE SHEET)

ETHICAL REVIEW COMMITTEE, ICDDR,B.

226

Principal Investigator TASNIM AZIM Trainee Investigator (if any) _____

Application No, 90-020 Supporting Agency (if Non-ICDDR,B) _____

Title of Study THE ROLE OF IMMUNE Project status:
(DYS)FUNCTION IN PERSISTENT (✓) New Study
DIARRHOEA OF CHILDHOOD () Continuation with change
() No change (do not fill out rest of form)

Circle the appropriate answer to each of the following (If Not Applicable write NA).

1. Source of Population:
 - (a) Ill subjects Yes No
 - (b) Non-ill subjects Yes No
 - (c) Minors or persons under guardianship Yes No
 2. Does the study involve:
 - (a) Physical risks to the subjects Yes No
 - (b) Social Risks Yes No
 - (c) Psychological risks to subjects Yes No
 - (d) Discomfort to subjects Yes No
 - (e) Invasion of privacy Yes No
 - (f) Disclosure of information damaging to subject or others Yes No
 3. Does the study involve:
 - (a) Use of records, (hospital, medical, death, birth or other) Yes No
 - (b) Use of fetal tissue or abortus Yes No
 - (c) Use of organs or body fluids Yes No
 4. Are subjects clearly informed about:
 - (a) Nature and purposes of study Yes No
 - (b) Procedures to be followed including alternatives used Yes No
 - (c) Physical risks Yes No NA
 - (d) Sensitive questions Yes No NA
 - (e) Benefits to be derived Yes No NA
 - (f) Right to refuse to participate or to withdraw from study Yes No
 - (g) Confidential handling of data Yes No
 - (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No NA
 5. Will signed consent form be required:
 - (a) From subjects Yes No
 - (b) From parent or guardian (if subjects are minors) Yes No
 6. Will precautions be taken to protect anonymity of subjects Yes No
 7. Check documents being submitted herewith to Committee:
 - ___ Umbrella proposal - Initially submit an overview (all other requirements will be submitted with individual studies).
 - Protocol (Required)
 - ___ Abstract Summary (Required)
 - ___ Statement given or read to subjects on nature of study, risks, types of questions to be asked, and right to refuse to participate or withdraw (Required)
 - ___ Informed consent form for subjects
 - Informed consent form for parent or guardian
 - ___ Procedure for maintaining confidentiality
 - ___ Questionnaire or interview schedule *
- * If the final instrument is not completed prior to review, the following information should be included in the abstract summary
1. A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.
 2. Examples of the type of specific questions to be asked in the sensitive areas.
 3. An indication as to when the questionnaire will be presented to the Cttee. for review.

We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.

TASNIM AZIM

A-032078

98-020
2/2/12/90

APPLICATION FOR PROJECT GRANT

- 1. PRINCIPAL INVESTIGATOR : Dr. Tasnim Azim
- COINVESTIGATORS : Dr. Laila Noor Islam
Dr. Firdausi Qadri
Mr. M. A. Wahed
Dr. Michael Louis Bennish
Dr. Jena Derakhshani Hamadani
- 2. TITLE OF THE PROJECT : The role of immune (dys)function in persistent diarrhoea of childhood
- 3. STARTING DATE : As soon as possible
- 4. COMPLETION DATE : 3 years from starting date
- 5. TOTAL BUDGET REQUESTED : US\$ 206,988
- 6. FUNDING SOURCE :
- 7. PROGRAMME COORDINATOR : Associate Director
Laboratory Sciences Division



8. AIMS OF THE PROJECT

a) General aim

To identify immune abnormalities that may possibly play a role in precipitating persistent diarrhoea; this will be done by comparing the immune response of children who develop persistent diarrhoea with those who recover from the acute illness.

b) Specific aims

- 1) Identification of possible alterations in granulocytic and lymphocytic populations and defence mechanisms in diarrhoeal children which may preclude recovery and lead to diarrhoeal persistence.
- 2) Assessment of the role of cytokines in diarrhoeal persistence in children.

- 3) Insights into the immunopathogenesis of persistent diarrhoea in general and in Bangladeshi children in particular.

c) Significance

This study will assess whether immunological abnormalities play a role in precipitating persistent diarrhea in children by carrying out a systematic investigation of granulocytic and lymphocytic responses and cytokine levels.

8. ETHICAL IMPLICATION

The following children will be studied:

| Disease condition | No. of children | Age of children (months) | Source of children |
|------------------------|-----------------|--------------------------|-----------------------------------|
| Acute watery diarrhoea | ~150 | 7-24 | ICDDR,B |
| Persistent diarrhoea | 30 | 7-24 | ICDDR,B |
| Malnutrition | | | |
| 1st degree | 30 | 7-24 | ICDDR,B |
| 2nd degree | 30 | 7-24 | ICDDR,B |
| 3rd degree | 30 | 7-24 | ICDDR,B and Dhaka Shishu Hospital |
| Healthy controls | 30 | 7-24 | ICDDR,B and Dhaka Shishu Hospital |

The required sample, n , for estimating different immunological parameters for each of the groups has been obtained using the following equation:

$$n = \frac{2 \delta^2}{\epsilon^2}$$

Where α is the value of normal variate for which the estimated value will be within $\pm\epsilon$ of the population value with a probability of $(1-2\alpha)$. We have considered the variances of different immunological markers and found that a sample size of 30 is sufficient to limit the error within 20% of the population parameter with 95% confidence level.

Children between the ages of 7 mths-2 yrs who have been suffering from watery diarrhoea for 7 ± 1 days will be enrolled in the study. A rough estimate suggests that around 20% of these children will develop persistent diarrhoea. Therefore, 150 children with acute diarrhoea will have to be enrolled initially to obtain 30 with persistent diarrhoea. However, since this is a rough estimate, the number may vary.

The children will be clinically evaluated daily by a physical examination, measurements of height, weight and temperature. Microscopic examination for cellular elements in stool will be carried out. The haemoglobin percentage and total and differential leucocyte count will be measured in blood. The nutritional status of the children will be assessed by calculating weight for age and will be classified as follows:

| | |
|-------------------------|--------------------------------|
| 1st degree malnutrition | 90-75% of NCHS 50th percentile |
| 2nd degree malnutrition | 75-60% of NCHS 50th percentile |
| 3rd degree malnutrition | <60% of NCHS 50th percentile |

Control children will be matched for age and nutrition and will therefore include children with 1st, 2nd or 3rd degree malnutrition. Healthy children without malnutrition will also be included. Children with malnutrition will be obtained from the nutrition rehabilitation unit of ICDDR,B while healthy

controls will be obtained from Dhaka Shishu Hospital or siblings of patients at ICDDR.B.

Samples of blood, saliva and stool will be collected from all children. Seven mls of venous blood will be drawn at initial enrollment and 14-15 days after the onset of diarrhoea, if diarrhoea persists. Stool and saliva will be taken on the same day; saliva will be collected at least 1 hr after the last feed using a clean plastic pipette. In addition, delayed type hypersensitivity (DTH) will be tested on the forearm of the children. Control children will provide single samples of blood, stool and saliva and undergo one test for DTH.

The study will not interfere with the management and treatment of the children and none of the procedures will be harmful. A written consent will be obtained from the guardian.

9. BACKGROUND

One of the definitions of persistent diarrhoea is the passage of an increased volume of watery stool for a period longer than 2 weeks (Walker-Smith, 1988). A wide range of clinical and pathological conditions are covered by this definition, however, this study will concentrate only on those cases where persistent diarrhoea follows an episode of acute diarrhoea.

Studies in rural and urban Bangladeshi children under 4 years with diarrhoea reveal that 4% of these are persistent (Henry, 1987). Most children admitted to the Treatment Centre of the ICDDR,B are severely ill with malnutrition, malabsorption and often secondary infections such as bronchopneumonia; a fatal outcome in these children is not uncommon. The cause/causes of development of

persistent diarrhoea is/are unknown. Some conditions have however been associated with persistent diarrhoea including:

1. Infections

There are reports of isolation of bacterial, parasitic and viral pathogens from cases of persistent diarrhoea. They include *Shigella* spp., *Campylobacter jejuni*, *E. coli*, *Giardia lamblia*, rotavirus and *Cryptosporidia*. However, Shahid *et al.* (1988) have shown that the incidence of isolation is similar to that of acute diarrhoea. Furthermore, in many cases no pathogen can be isolated; Roy *et al.* (1989) isolated a pathogen in only 1/26 patients with persistent diarrhoea. These findings suggest that although enteric pathogens are instrumental in some cases of persistent diarrhoea, there may be an underlying condition preventing recovery from the acute illness.

2. Carbohydrate malabsorption

Transient carbohydrate malabsorption may accompany acute bouts of diarrhoea due to a decrease in disaccharidase enzymes and/or a decrease in surface villous area (Phillips *et al.*, 1980). The reason for persistence of carbohydrate malabsorption is not understood again suggesting an underlying pathophysiology of absorption.

3. Cow's milk and soy protein intolerance

Cow's milk allergy is characterised by an early age onset (mean age is 9 weeks) (Kuitunen *et al.*, 1975). It causes a spectrum of problems including persistent diarrhoea. Diagnosis is made by an acute challenge of milk which precipitates the symptoms and the child improves when cow's milk is withdrawn.

Some of these children may also be sensitive to soy protein (Whittington and Gibson, 1977). In Malaysia, cow's milk allergy has been reported to be relatively high (Iynykaran et al, 1979). Although the condition does occur in Bangladesh there is no official estimation of its incidence rate.

Certain risk factors for persistent diarrhoea have also been identified such as nutritional status, environment and breast feeding. Studies in Bangladesh have shown that 28% of all deaths in children under 5 years are associated with persistent diarrhoea and malnutrition (Fauveau, 1986). However, the exact relationship between malnutrition and persistent diarrhoea is not clear. Black *et al.* (1984) have shown that children with malnutrition have diarrhoea for longer durations than well nourished children but Koster *et al.* (1987) found no correlation between the two. Snyder and Merson (1982) have shown that persistent diarrhoea is more common in children living in poor environmental conditions which may be related to contamination of water and weaning foods (Black *et al.*, 1982). Moreover, in children under 2 years, the incidence of persistent diarrhoea is less if they are breast fed which further strengthens the relationship between faecal contamination of food and persistent diarrhoea. On the other hand, persistent diarrhoea is not limited to children living in poor environmental conditions (Roy *et al.*, 1989).

Thus, no specific cause can be attributed to persistent diarrhoea. Because of the association of persistent diarrhoea with malabsorption and which can lead to malnutrition, it is treated as a nutritional disorder. The management of persistent diarrhoea, therefore, concentrates largely on dietary and empirical antimicrobial therapy. Although treatment with different diets can be effective it is only partially successful; studies on dietary therapy (Roy *et al.*, 1989) and nutrient absorption (Roy *et al.*, 1990) at the Treatment

Centre for ICDDR,B stress the need for more intensive analyses of the condition. There are ongoing studies on enzyme (amylase) levels, more effective diets and on the microbiology of the gut with particular reference to enteric pathogens at ICDDR,B. However, there are no studies addressing the role of immunopathology in precipitating persistent diarrhoea.

Very little is known about the role of the immune status of the child in the development of persistent diarrhoea. Malnutrition is frequently associated with persistent diarrhoea and the nutritional status is a well recognised determinant of immunocompetence. It is therefore expected that children with persistent diarrhoea will have lowered immunity. However, their lowered immunity may not entirely be related to nutritional status. A preliminary prospective study carried out on Bangladeshi children identifies susceptibility to frequent attacks of diarrhoea of longer duration in children with decreased cell mediated immunity (Koster *et al.*, 1987). Regression analyses of the data reveals that the development of prolonged diarrhoea is related to decreased immunity rather than malnutrition. Based on these preliminary findings, our hypothesis is that immunocompetence could be an important determinant in the development of persistent diarrhoea. This study will investigate this hypothesis by comparing the immune responses of children who recover from acute diarrhoea with those children in whom diarrhoea persists. The following questions will be addressed in this study:

1. Is there an underlying cellular immune defect which is associated with persistence of diarrhoea?

The cellular immune response is mediated by T and B lymphocytes both of which arise from stem cells in the bone marrow. T lymphocytes mature in the thymus from where two populations emerge, CD2+, CD3+, CD4+ (helper/suppressor-

inducer) and CD2+, CD3+, CD8+ (suppressor/cytotoxic) cells. These mature T lymphocytes are functionally competent and on exposure to antigen can mediate help or suppression of other cells or effect cytotoxicity. Studies from our Centre (Koster *et al.*, 1987) which show that decreased cell mediated immunity causes children to suffer from prolonged bouts of diarrhoea, measured cell mediated immunity by delayed type hypersensitivity responses (DTH). In DTH, antigenic peptides are presented by antigen presenting cells and recognised by CD4+ T lymphocytes in association with MHCII antigens. On activation, these cells secrete soluble factors which recruit CD8+, cytotoxic T lymphocytes and macrophages to destroy the antigen. Decreased DTH responses therefore suggest either a decrease/lack of mature T lymphocytes or an inability of mature T lymphocytes to respond to antigen. Inability to respond to antigen may be due to an increase in suppressor cells or the release of inhibitory factors. We will investigate these hypotheses by assessing the percentage of mature CD3+ T lymphocytes in the peripheral blood and the percentages of CD4+ and CD8+ T lymphocytes. In addition, the proliferative responses to known T lymphocyte mitogens will be tested.

B lymphocytes develop in the bone marrow and mature B lymphocytes expressing surface IgM (sIgM) enter the circulation. On exposure to antigen, sIgM+ B lymphocytes become activated, switch to other Ig isotypes, proliferate and give rise either to memory cells or Ig secreting plasma cells. Activation of B lymphocytes may be T lymphocyte-dependent or -independent. T lymphocyte-dependent activation of B lymphocytes relies on help from CD4+ T lymphocytes. If CD4+ T lymphocytes are decreased in number or unable to function, T-dependent B lymphocyte proliferation will be reduced or absent and this can be measured *in vitro* by assessing proliferation in response to T lymphocyte-dependent B lymphocyte mitogens.

2. Do dysfunctional granulocytes contribute to the development of persistent diarrhoea?

Like lymphocytes, granulocytes arise in the bone marrow from stem cells and mature into functional granulocytes under the influence of various haemopoietic factors. From the bone marrow granulocytes enter the circulation and become available for defence against external antigen. For optimal defence, neutrophils must first adhere to endothelial cells, migrate through the blood vessels, engulf the antigen and degranulate. As in many cases of persistent diarrhoea microorganisms can be isolated, it is possible that the granulocytes in these children have a functional defect. Hill et al (1977) found that in children suffering from recurrent episodes of otitis media and chronic diarrhoea there is a decrease in neutrophil chemotaxis. We will examine the functional responses of neutrophils to known neutrophil stimulants and relate functional changes, if any, to the development of persistent diarrhoea.

3. Are there altered levels of circulating cytokines such as interleukin 1 (IL1) and tumour necrosis factor (TNF α)?

IL1 is a pleiotropic cytokine secreted by many cell types most notably macrophages. There are 2 types of IL1- IL1 α and IL1 β . Although IL1 β is predominant, the activities of IL1 α and IL1 β are almost overlapping. IL1 has a wide range of effects and mediates systemic acute phase responses, as well as local tissue inflammation. Thus, it induces fever, hypoglycaemia, acute phase protein synthesis, stimulates lymphocytes and the production of granulocytes, elicits production of other cytokines including colony stimulating factors, etc. The release of IL1 is stimulated by microorganisms, endotoxin, antigen-antibody complexes, cytokines such as TNF and complement components such as C5a. Therefore, infection, trauma or any inflammatory

process will stimulate IL1 production any of which may be operative in persistent diarrhoea.

TNF α (cachectin) is similar to IL1 in its actions and production. TNF α is a critical mediator of septic shock syndrome. Its secretion is stimulated by endotoxin and C5a. TNF α may also, therefore, be increased in persistent diarrhoea.

In addition to answering the above specific questions, the study will provide a better understanding of the immunopathogenesis of persistent diarrhoea in children from developing countries who are not only nutritionally compromised but also subject to repeated infections. Because of the unique location of ICDDR,B - in a country in which the incidence is reasonably high - and the Centre's technical competence and availability of basic equipment, it is the most likely place in which some of these questions can be answered.

RESEARCH PLAN

Tests will be carried out on

- i) Peripheral blood
- ii) Saliva and stool
- iii) Delayed type hypersensitivity (DTH)

a) Peripheral blood

Peripheral blood will be used for experiments on serum, plasma, lymphocytes (mononuclear cells) and granulocytes. Seven mls of peripheral blood will be required from children and this will be obtained by venepuncture. In those cases where less blood is obtained, some tests will not be carried out. The plan is shown below:

PERIPHERAL BLOOD (7-10 ml maximum)

→ 1.0 ml
1. C₃, C₄ levels
2. Protein fractions
2 ml for cytokines ←

↓
4 ml in heparin containing tube
separated on Ficoll-Hypaque

→ PLASMA will be collected from
above the band of mononuclear
cells and used for:
1. IgG, IgM and IgA levels
2. CRP, iron, transferrin or
ferritin, zinc
3. Ig to diphtheria and tetanus
4. Autologous plasma for use in
other tests

← GRANULOCYTES will be
obtained from the pellet
after removal of RBC by
hypotonic lysis and
Dextran sedimentation.
Cells will be used for:

1. Phagocytosis →
1 x 10⁶ cells
2. Chemotaxis →
1 x 10⁶ cells
3. Polarisation →
2 x 10⁶ cells

↓
MONONUCLEAR CELLS

- will be obtained by collecting
the band at the interface and used for:
1. Resting DNA synthesis → 2 x 10⁵ cells
 2. PHA stimulation → 1.0 x 10⁶ cells
 3. PWM stimulation → 4.0 x 10⁵ cells
 4. Con A stimulation → 4.0 x 10⁵ cells
 5. Phenotyping by
immunofluorescence → 2.0 x 10⁶ cells

Research plan

a) Serum

1. C3, C4 levels will be measured by a discrete analyser (COBAS B10). This will be done to control for malnutrition where C3 levels may be lowered.
2. Protein fractions will be estimated by electrophoresis.

b) Plasma

1. IgG, IgA, IgM will be measured by COBAS BIO. Besides providing us information of possible immunoglobulin (Ig) alterations in persistent diarrhoea, any change will reflect alterations in cellular immune responses.
2. Igs to diphtheria (neutralisation test) and tetanus (ELISA) will be assessed if the children have been immunised against these antigens. These specific Igs will be a measure of the overall immune status of the children and complement DTH tests.
3. C reactive protein will be measured by COBAS BIO to assess the extent of underlying inflammation.
4. Zinc (by an atomic absorption spectrophotometer), iron and transferrin/ferritin (by COBAS BIO) will be measured as these have profound effects on immunity and may be lowered in malnutrition.
5. Cytokines
For the assay of these cytokines, 2 ml of blood will be added to a purple top EDTA containing vacutainer tube to which the protease inhibitor aprotinin has been added (to inhibit enzymatic

degradation of cytokines). The tube will be immediately put on ice, and then centrifuged at approximately 3000 rpm for 5 minutes. The plasma (excluding the buffy coat) will be aspirated, and transferred to a 1.5 ml Eppendorf tube, and then be subjected to a hard-spin (1,000 rpm) in a microfuge in order to completely sediment any remaining white cells or platelets. The supernatants will then again be aspirated, placed in storage vials, and stored at -70°C. The vials will be transported to Tufts University, Boston for assaying cytokine levels. Assay of IL1 α and IL1 β and TNF will be done using a radioimmunoassay method. Sensitivities of the assay are typically 80 pg/ml (IL1 β) 40 pg/ml (IL1 α) and 10 pg/ml (C/TNF). There is no crossreactivity of the antibodies used in these assays with other leukocyte-derived factors.

Cytokine levels are important indicators of underlying tissue damage and their measure, therefore, has considerable significance in this study. However, as these tests are expensive and have to be carried out in the US, they will be excluded from the study, if the budget provided is inadequate.

c) Mononuclear cells

1. Resting DNA synthesis will be measured by incubating mononuclear cells with ³HTDR for 3 hrs. to assess purification.
2. Phytohaemagglutinin (PHA) (a T lymphocyte mitogen) stimulation will be measured by culturing cells with PHA in the presence of autologous plasma, heterologous plasma or calf serum for 72 hours and assessing proliferation by ³HTDR incorporation.

3. Pokeweed mitogen (PWM) (A T-dependent B lymphocyte mitogen) stimulation will be measured by culturing cells with PWM or Con A in the presence of autologous plasma, heterologous plasma or calf serum for 5 days and assessing proliferation by ³HTDR incorporation. A similar experiment will be conducted with concanavalin A (con A) (a T lymphocyte mitogen). Where cell numbers are inadequate, PHA stimulation will be excluded from the study.

4. Phenotyping by indirect immunofluorescence will be carried out for determining proportions of T cells, B cells and T cell subsets (T helper cells or CD4 and T suppressor/cytotoxic cells or CD8) using monoclonal antibodies UCHT1 (a kind gift of Prof. P.C.L. Beverley), B1 (CD20) (commercial source), anti-CD4 (a kind gift of Dr. G. Sattentau) and UCHT4 (from Prof. P.C.L. Beverley) respectively.

d) Granulocytes

1. Phagocytic index - neutrophils will be incubated with baker's yeast suspension and pooled human serum from 6 healthy controls for 60 minutes. Cells will then be centrifuged and resuspended in a drop and a smear made on a glass slide and stained with Wright's stain. Ingested yeast in 50 neutrophils will be counted under a microscope.

2. Neutrophil chemotaxis will be measured by using a Boyden chamber. Neutrophils will be placed in the upper chamber, the chemotactic

peptide N-formyl-Met-Leu-Phe (FMLP), layered in the lower chamber and PBS (phosphate buffer saline) added to both. After incubation for 30 minutes, the filters will be removed, fixed in methanol and stained in haematoxylin and then counted under a microscope.

3. Morphological polarisation of neutrophils-neutrophils will be incubated with FMLP for 30 mins at 37°C. The cells will then be fixed with glutaraldehyde, washed and scored for the proportion of neutrophils deviating from spherical morphology.

b) Saliva and stool

Saliva collected will be heat-inactivated and centrifuged. ELISAs will be carried out on the clear supernatant to measure total Ig and IgA. Igs to polio virus will also be tested by a neutralisation assay if the children have been immunised against polio.

Stool samples will be homogenised by mixing thoroughly in phosphate buffered saline and centrifuged. ELISA to determine Ig levels will be carried out on the clear supernatant.

These tests will be a measure of the response of the mucosal immune system.

c) Delayed type hypersensitivity (DTH)

DTH will be tested using a Multitest CMI kit whereby 7 antigens and a control will be introduced intradermally into the forearm using a multiple puncture device. An induration of 2mm or more diameter after 48 hrs will be counted as a positive reaction. The antigens that will be tested include:

| | |
|--|---------------------------|
| 1. Tetanus antigen | 550,000 Merieux units/ml |
| 2. Diphtheria antigen | 1100,000 Merieux units/ml |
| 3. Streptococcus antigen (group C) | 2,000 Merieux units/ml |
| 4. Tuberculin antigen | 300,000 IU/ml |
| 5. Glycerin control : solution of glycerin to 70% weight/volume | |
| 6. Candida antigen (albicans) | 2,000 Merieux units/ml |
| 7. Trichophyton antigen (mentagrophytes) | 150 Merieux units/ml |
| 8. Proteus antigen (mirabilis) | 150 Merieux units/ml |

The t-test will be used to calculate the statistical significance of each measure, comparing the treatment group with the control group.

BIBLIOGRAPHY

- Black RE, Brown KH and Becker S. (1984) Malnutrition is a determining factor in diarrhoeal duration, but not incidence, among young children in a longitudinal study in rural Bangladesh. *Am J Clin Nutr.* 39:87-94.
- Black RE, Brown KH, Becker S *et al.* (1982) Contamination of weaning foods and transmission of enterotoxigenic *Escherichia coli* diarrhoea in children in rural Bangladesh. *Trans Roy Soc Trop Med Hyg.* 76:259-264.
- Fauveau V. (1986) Deaths of children younger than 5 years in Matlab. *Ann Rept ICDDR,B* p.12.
- Henry FJ. (1987) Persistent diarrhoea and malnutrition in urban and rural Bangladesh. *Ann Rept ICDDR,B* P.13.
- Hill HR, Book LS, Hemming VG *et al.* (1977) Defective neutrophil chemotactic responses in patients with recurrent episodes of otitis media and chronic diarrhoea. *Am J Dis Child.* 131:433-436.
- Iyngkaran N, Abdin Z, Davis K *et al.* (1979) Acquired carbohydrate intolerance and cow milk protein-sensitive enteropathy in young infants. *J. Peds.* 95:373-378.
- Koster FJ, Palmer DL, Chakraborty J *et al.* (1987) Cellular immune competence and diarrhoeal morbidity in malnourished Bangladeshi children: a prospective field study. *Am J Clin Nutr.* 46:115-120.
- Kuitunen P, Visakorpi JK, Savilahti E *et al.* (1975) Malabsorption syndrome with cow's milk intolerance. *Arch Dis Child.* 50:351-356.
- Phillips AD, Avigad S, Sacks J *et al.* (1980) Microvillous surface area in secondary disaccharidase deficiency. *GUT* 21:44-48.

- Roy SK, Alam AN, Majid N *et al.* (1989) Persistent diarrhoea: a preliminary report on clinical features and dietary therapy in Bangladeshi children. *J Trop Ped.* 35:55-59.
- Roy SK, Haider R, Akbar MS *et al.* (1990) Persistent diarrhoea: clinical efficacy and nutrient absorption with a rice based diet. *Arch Dis Child.* 65:294-297.
- Shahid NS, Sack DA, Rahman M *et al.* (1988) Risk factors for persistent diarrhoea. *Brit Med J.* 297:1036-1038.
- Snyder JD and Merson MH. (1982) The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. *Bull WHO.* 60:65.
- Walker-Smith J. (1988) Intractable diarrhoea. In: Diseases of the small intestine in childhood. Butterworths, London, Boston, Singapore, Sydney, Toronto, Wellington. p.390.
- Whittington PF and Gobson R. (1977) Soy-protein intolerance: four patients with concomitant cow's milk intolerance. *Peds.* 59:730-732.

11. PUBLICATIONS OF INVESTIGATORS (last five years)

a) Dr. Tasnim Azim

-
1. Azim I, Allday MJ and Crawford DH. (1990) Immortalization of Epstein-Barr virus-infected CD23-negative B lymphocytes by the addition of B cell growth factor. *J. Gen. Virol.*, 71:665-671.
 2. Azim I and Crawford DH. (1988) Lymphocytes activated by the Epstein-Barr virus to produce immunoglobulin do not express CD23 or become immortalised. *Int. J. Cancer.*, 42:23-28.
 3. Crawford DH, Azim I, Daniels GL and Huehns ER. Monoclonal antibodies to the Rh D antigen. In: Progress in Transfusion Medicine III. Ed. J. Cash. Churchill Livingstone Press, pp.175-197.
 4. Azim I, Golay J, Lam K and Crawford DH. (1987) Polyclonal activation of B lymphocytes after EB virus infection. In: The Proceedings of the 2nd International Workshop on EB Virus and Related Malignant Diseases. pp.331.
 5. Crawford DH and Azim I. (1987) The use of EB virus for the production of human monoclonal antibody secreting cell lines. In the Proceedings of the 1st IRI International Symposium on Biotechnology: Monoclonal antibodies in the treatment of human disease. Ed. J. Brown, pp.1-6.
 6. Azim I, Crawford DH and Beverley PCL. (1987) The role of activation antigens on the surface of B cells. In: Leucocyte Typing III, Eds. A.J. McMichael *et al.*. Oxford University Press, pp.559-561.

7. Sutherland S, Crawford DH, Wilson SA, Morgan B, Azim I and Huehns ER. (1987) Production and characterisation of a human monoclonal antibody to cytomegalovirus and its use in an early nuclear fluorescence assay. J. Med. Virol., 22:245-255.
 8. Morgan-Capner P, Morris JA, McIlmurray MB, Thomas JA, Crawford DH and Azim I. (1986) Immunohistological studies of lymphoproliferative lesions in a fatal case of Epstein-Barr virus infection. J. Clin. Pathol., 39:1317-1322.
 9. Berliner N, Duby AD, Linch DC, Murre C, Quetermous T, Knott LJ, Azim I, Newland AC, Lewis DL, Galvin MC and Seidman JG. (1986) T cell receptor gene rearrangements define a monoclonal T cell proliferation in patients with T cell lymphocytosis and cytopenia. Blood, 67:914-918.
- b) Dr. Laila N. Islam

1. Islam LN and Wilkinson PC. (1989) Evaluation of methods for isolating human peripheral blood monocytes. J. Immunol. Meths. 121:75-84.
 2. Wilkinson PC. and Islam LN. (1989) Recombinant IL-4 and IFN- γ activate locomotor capacity in human B lymphocytes. Immunol, 67:237-243.
 3. Islam LN and Wilkinson PC. (1988) Chemotactic factor-induced polarization, receptor redistribution and locomotion of human blood monocytes. Immunology, 64:501-507.
 4. Wilkinson PC, Islam LN, Sinclair D and Dagg JH. (1988) The defect of lymphocyte locomotion in chronic lymphocytic leukaemia: studies of polarization and growth-dependent locomotion. Clin. Experim. Immunol., 71:497-501.
 5. Wilkinson PC, Lackie JM, Haston WS and Islam LN. (1988) Effects of phorbol esters on shape and locomotion of human blood lymphocytes. J. Cell Sci., 90:645-655.
 6. Islam LN, McKay IC and Wilkinson PC. (1985) The use of collagen or fibrin gels for the assay of human neutrophil chemotaxis. J. Immunol. Meth., 85:137-151.
 7. Noor L and Khan NH. (1982) Studies on ninhydrin positive compounds present in some seeds. Dhaka Univ. Stud., Part-B, 30(1):99-105.
 8. Khan NH, Noor L, Begum M and Rahman M. (1981) Studies on the antibacterial activity of some indigenous plant extracts. Bangladesh J. Biol. Sci., 10:31-38.

c) Dr. Firdausi Qadri

- 1) Yasmeen T and Qadri F. 1984. Purification of alkaline phosphatase from human placenta. J Chromatog, 315:425.
- 2) Qadri F. 1985. The reactive triazine dyes--their usefulness and limitation in protein purifications. Trends in Biotechnol, 3:7.
- 3) Shameem GMM, and Qadri F. 1987. Isolation and Purification of Seminoma Alkaline Phosphatase. Clin Chem, 33(2):248-252.
- 4) Qadri F, Hossain SA, Ciznar I, Haider K, Ljungh A, Wadstrom T, and Sack DA. Congo red binding and salt aggregation tests as indicators of virulence in *Shigella* species. J Clin Microbiol, 27:1343-1348.
- 5) Qadri F, Haq S and Ciznar I. 1989. Hemagglutinating properties of *Shigella dysenteriae* type 1 and other *Shigella* species. Infect Immun, 57:2909-2911.
- 6) Sayeed S, Sack DA and Qadri F. 1989. Cross-reacting antigens between *Plesiomonas shigelloides* 0:17 and *Shigella sonnei*. Bangladesh J Microbiol, 6:7-12.
- 7) Haider K, Azad K, Qadri F, Nahar S and Ciznar I. 1990. Role of plasmids in virulence-associated attributes and in O-antigen expression in *Shigella dysenteriae* type 1 strains. J Med Microbiol, 33.
- 8) Qadri F, Raqib R, Hussain IA, and Ciznar I. Cell surface proteins from *Shigella dysenteriae* type 1. Zentralblatt für Bakteriologie. Mikrobiologie und Hygiene. Series A (in press).

d) Mr. M. A. Wahed

1. Alam AN, Abdal NM, Rao B, Wahed MA, Rahaman MM. *et al.* (1987) Plasma prostacyclin levels during the haemolytic-uraemic syndrome. In: Proceedings of 4th Asian Conference on Diarrhoeal Diseases, p.60.
2. Sarker SA, Wahed MA, Rahaman MM, Alam AN, Khanom A and Jahan F. (1986) Persistent protein losing enteropathy in postmeasles diarrhoea. Arch. Dis. Childhood, 61(8):739-743.
3. Sarker SA, Wahed MA, Alam AN, Khanom and Rahaman MM. (1985) Protein-losing enteropathy syndrome in postmeasles diarrhoea. In: Proceedings of 3rd Asian Conference on Diarrhoeal Disease, Bangkok, p.70.
4. Samadi AR, Ahmed SM, Bardhan PK, Huq MI and Wahed MA. (1985) Treatment of infantile diarrhoea with standard ORS and early introduction milk feeds. J. Trop. Pediat., 31(3):162-166.

5. Ali A and Wahed MA. (1984) Preparation and quality control of hand packaged oral rehydration salt sachets. *J. Diar. Dis. Res.*, 2(3):1162-167.
6. Samadi AR, Wahed MA, Islam R and Ahmed M. (1983) Consequence of hyponatremia and hypernatremia in children with acute diarrhoea in Bangladesh. *Br. Med. J.*, 286:671-673.
7. Samadi AR, Wahed MA and Islam R. (1983) Comparison of osmolarity of milk feed with breastmilk. *Nutr. Rep. Int.*, 28(5):111-114.
8. Rahaman MM and Wahed MA. (1983) Direct nutrient loss and diarrhoea. In: *Diarrhoea and Malnutrition*, ed. Chen and Scrimshaw, pp.155-160.

Dr. M. L. Bennish

1. Bennish M, Weinstein RA, Kabins SA and Jain M. False localization of the site of endocarditis by cardiac catheterization with quantitative cultures. *Am J Clin Pathol*, 1985; 83:130-131.
2. Butler I, Bennish M, Schachter J and Stoll B. Serologic evidence of chlamydial infection in patients with diarrhea. *Trans Roy Soc Trop Med Hyg*, 1985; 79:42-43.
3. Briend A, Dykewicz C, Graven K, Mazumder RN, Wojtyniak B and Bennish M. Assessing the risk of death for malnourished children: How useful are nutritional indices and nutritional classification? *Br Med J*, 1986; 293:373-375.
4. Kelly M, Donohue-Rolfe A, Bennish M and Keusch GT. Enzyme-linked immunosorbent assay for shigella toxin. *J Clin Micro*, 1986; 24:65-68.
5. Bennish M. The Bangladesh drug policy: The next step - using good drugs "goodly." *Bangladesh J of Child Health*, 1987; 11:63-72.
6. Rahman O, Bennish M, Alam A and Salam MA. Rapid intravenous rehydration by means of a single polyelectrolyte solution with or without dextrose. *J Pediatr*, 1988; 113:654-660.
7. Salam MA and Bennish ML. Therapy for shigellosis, I. Randomized, double blind trial of nalidixic acid in childhood shigellosis. *J Pediatr*, 1988; 113:901-907.
8. Ronsmans C, Bennish ML and Wierzba T. Diagnosis and management of dysentery by community health workers. *Lancet*, 1988; ii:552-555.
9. Struelens MJ, Mondon G, Bennish ML and Dance DAB. Meloidosis in Bangladesh. *Trans Roy Soc Trop Med Hyg*, 1988; 82:777-778.
10. Keusch GT and Bennish ML. Shigellosis: Recent progress, persisting problems and research issues. *Pediatr Infect Dis J*, 1989; 8:713-719.

11. van Loon FPL, Bennish ML, Speelman P and Butler T. Randomized double blind trial of loperamide for the treatment of watery diarrhea in expatriates in Bangladesh. *Gut*, 1989; 30:492-495.
12. Bennish ML. Summary report from the committee on antibiotic use in diarrhea. In: Daschner FO. WHO symposium: use and abuse of antibiotics worldwide. *Infection*, 1989; 17:55-57.
13. Bennish ML, Harris J and Wojtyniak BJ. Death in shigellosis: incidence and risk factors in hospitalized patients. *J Infect Dis*, 1990, 161:500-506.
14. Bennish ML, Azad AK, Rahman I and Phillips RE. Hypoglycemia during childhood diarrhea: incidence, pathophysiology and outcome. *N Engl J Med*, 1990; 322:1357-1363.
15. Bennish ML, Salam MA, Haider R and Barza M. Therapy of shigellosis. II. Randomized, double blind comparison of ciprofloxacin and ampicillin. *J Infect Dis*, 1990; 162:Sept (in press).
16. Salam MA and Bennish MA. Antimicrobial therapy of shigellosis. *Rev Infect Dis*, (in press)
17. Bennish ML. Potentially lethal complications of shigellosis. *Rev Infect Dis* (in press).
18. Bennish ML. Mortality from shigellosis. Community and hospital data. *Rev Infect Dis* (in press).
19. Ronsmans C, Bennish ML, Chakraborty J and Fauveau V. Dysentery in rural Bangladesh: current treatment practices. *Rev Infect Dis* (in press).
20. Strulens M, Bennish M and Mondal G. Bacteremia during diarrhea: incidence, etiology, risk factors and outcome. *Am J Epidemiol* (in press).
21. Bennish ML, Azad AK and Yousefzadeh D. Intestinal obstruction during shigellosis: incidence, clinical features, risk factors and outcome. *J Infect Dis* (submitted).
22. Bennish ML, Salam MA and Wahed MA. Enteric protein loss during shigellosis. *Am J Clin Nutr* (submitted).
23. Keusch GT, Formal SA and Bennish ML. Shigellosis. In: Warren KS, Mahmoud AAF eds. *Tropical and Geographic Medicine*, 2nd edition, New York, McGraw-Hill Book Inc., 1989; 762-776.
24. Keusch GT and Bennish ML. Shigellosis. In: Farthing MJG, Keusch GT eds. *Enteric infection - Mechanisms, Manifestations and Management*. London, Chapman and Hall Medical, 1989, 265-282.

25. Keusch GT and Bennish GI. Shigellosis. In: Evans AS, Brachman P, eds. Bacterial Infections of Humans, 2nd edition. New York, Plenum Medical Book Company, 1990.
26. Bennish ML. Cholera. In: Rakel RE, ed. Conn's Current Therapy, 1991. Philadelphia, W.B. Saunders Company, 1990 (in press).

12. FLOW CHART

| Study population | No. of children | Time (3 years) |
|--------------------------|-----------------|---|
| Acute diarrhoea | ~150 | Children will be enrolled whenever available, preferably by 1½ years |
| Persistent diarrhoea | 30 | - as above - |
| Malnutrition: 1st degree | 30 | Samples will be obtained from children as and when they are available |
| 2nd degree | 30 | |
| 3rd degree | 30 | |
| Healthy controls | 30 | - as above - |

13. ITEMISED SPECIFIC TASK FOR EACH LISTED INVESTIGATOR

| Investigator/Task | Percentage of time involved |
|---|---------------------------------|
| a) Dr. T. Azim | 25% |
| <ul style="list-style-type: none"> - 1. Lymphocyte studies 2. DTH studies 3. Measurement of antibodies to diphtheria, tetanus and polio 4. Overall coordination | |
| b) Dr. L. N. Islam | 50% |
| Granulocyte studies | (of a 12-hour/week consultancy) |

- c) Dr. F. Qadri 10%
- Estimation of Ig levels in plasma,
saliva and stool
- d) Mr. M. A. Wahed 5%
- Estimations of Ig levels, serum
complement levels, iron,
transferrin/ferritin, CRP and zinc
levels in plasma by COBAS BIO and AAS
- e) Dr. J. D. Hamadani 10%
- Clinical assessment and management
of patients at ICDDR,B
- f) Dr. M. L. Bennisish
- Organise cytokine assays in the US

13. BUDGET

| | [in US\$] | | | |
|---|--------------------|---------------|---------------|----------------|
| | 1st year | 2nd year | 3rd year | Total |
| PERSONNEL | | | | |
| Dr. T. Azim | 6,000 | 6,600 | 14,519 | 27,119 |
| Dr. L. N. Islam | 1,100 | 1,221 | 2,500 | 4,821 |
| Mr. M. A. Wahed (5%) | | | 803 | 803 |
| Technician (2) | 4,950 | 5,445 | 12,100 | 22,495 |
| | <u>12,050</u> | <u>13,266</u> | <u>29,992</u> | <u>55,238</u> |
| SUPPLIES AND CHEMICALS | | | | |
| Plastics | 6,000 | 7,000 | 8,000 | 21,000 |
| Chemicals | 6,000 | 6,600 | 7,500 | 20,100 |
| Media, serum & other reagents | 8,500 | 9,500 | 10,000 | 28,000 |
| | <u>20,500</u> | <u>23,100</u> | <u>25,500</u> | <u>69,100</u> |
| HOSPITAL EXPENSES | 3,000 | 3,400 | 3,750 | 10,150 |
| MISCELLANEOUS, including mail, transport, fax, library, etc. | 4,500 | 5,000 | 5,500 | 15,000 |
| CYTOKINE ASSAYS | | 3,500 | 4,000 | 7,500 |
| 10% added costs | 9,000 | 10,000 | 11,000 | 30,000 |
| TRAVEL (to Tufts University for transporting plasma) | | | 3,500 | 3,500 |
| CAPITAL EXPENDITURE | | | | |
| Instruments and equipments including Co ₂ incubator, -20°C freezer 4°C refrigerator and maintenance | 10,000 | 3,500 | 3,000 | 16,500 |
| | <u>10,000</u> | <u>3,500</u> | <u>3,000</u> | <u>16,500</u> |
| TOTAL : | US\$ 59,050 | 61,766 | 86,172 | 206,988 |

TA:mh/T1:CYTOKIN3.PRT

INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH

CONSENT FORM

Your child is suffering from acute watery diarrhoea from which most children recover, but in a few, the diarrhoea persists. We do not know why some children develop persistent diarrhoea. As it causes considerable illness, sometimes death, we are carrying out a study to investigate its cause. We hope such a study will help us better understand the illness and thereby lead to its better treatment. We would like to enroll your child in this study. For the purpose of the study we require 7 mls of blood from your child, and a sample of saliva and stool. We will also carry out a skin test by pricking the forearm of your child at 8 small sites to assess his/her ability to combat infections. If the skin test is negative, we will vaccinate your child with the vaccines available at the Clinical Research Centre, ICDDR,B. If your child is still ill after another week, we will repeat all the samplings and tests. None of these procedures are harmful and they will not interfere with the usual care and treatment that is normally provided.

Your child will receive the usual care and treatment provided by the hospital irrespective of whether he/she participates in the study or not. If at any time you wish to withdraw your child from the study, you are free to do so. All the information obtained during the study will be confidential and, if you wish to know the results, they will be provided to you on request when they become available.

If you agree to let your child participate in the study, please sign or put your left thumb print impression below.

Signature (or left-thumb
print of guardian)

Date

Signature of investigator

Date

Signature of witness

Date

INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH

CONSENT FORM

We are conducting a study on children suffering from persistent diarrhoea. Persistent diarrhoea is a little understood condition in which diarrhoea persists for 2 weeks or more. As it causes considerable illness, sometimes death, we are investigating into its nature and cause. We hope such a study will help us better understand the illness and thereby lead to its better treatment. For this study we need to test not only children with persistent diarrhoea but also children without diarrhoea. We would, therefore, like to enroll your child in the study.

For the purpose of the study we require 7 mls of blood from your child and a sample of saliva and stool. We will also carry out a skin test by pricking the forearm of your child at 8 small sites to assess his/her ability to combat infections. The skin test will be read after 48 hours and if it is negative, we will vaccinate your child with the vaccines available at the Clinical Research Centre of ICDDR.B.

None of these procedures are harmful. All the information obtained during the study will be confidential and, if you wish to know the results, they will be provided to you on request when they become available.

If you agree to let your child participate in the study, please sign or put your left thumb print below.

Signature (or left-thumb
print of guardian)

Date

Signature of investigator

Date

Signature of witness

Date

Project title: The role of immune (dys)function in persistent diarrhoea of childhood.....

Principal Investigator(s): Drs. T. Azim, L.N. Islam, F. Qadir, M.L. Bennish and Mr.M.A. Wahed.

Summary of Referee's Opinions: Please see the following table to evaluate the various aspects of the proposal by checking the appropriate boxes. Your detailed comments are sought on a separate, attached page.

| | Rank Score | | |
|---------------------------------------|------------|--------|-----|
| | High | Medium | Low |
| Quality of Project | ✓ | | |
| Adequacy of Project Design | ✓ | | |
| Suitability of Methodology | ✓ | | |
| Feasibility within time period | ✓ | | |
| Appropriateness of Budget | ✓ | | |
| Potential value to field of knowledge | ✓ | | |

CONCLUSIONS

I support the application:

a) without qualification

b) with qualification:

- on technical grounds

- on level of financial support

I do not support the application

Name of Referee: DOROTHY H. CRAWFORD
 Position: PROFESSOR of MICROBIOLOGY
 Institution: LONDON SCHOOL of HYGIENE and TROPICAL MEDICINE

D Crawford
 Signature

1/9/90
 Date

DETAILED COMMENTS

Please briefly provide your opinions of this proposal, giving special attention to the originality and feasibility of the project, its potential for providing new knowledge and the justification of financial support sought; include suggestions for modifications (scientific or financial) where you feel they are justified.

(Use additional pages if necessary)

This research project aims to study the state of the immune system in children in Bangladesh with persistent diarrhoea and compare this with control children. The study described will yield general information about lymphocyte and neutrophil function, secretory antibody production and cytokine levels. The study has been well designed and makes best use of the small amounts of material available. It remains within the bounds of feasibility and should yield important results within the allotted timespan. These results will make a considerable contribution to our knowledge in this important field of research. I feel that the financial support is fully justified and I would wholeheartedly support the funding of this research project in full.

Project title: The role of immune (dys)function in persistent diarrhoea of childhood.

Principal Investigator(s): Drs. T. Azim, L.N. Islam, F. Qadri, M.L. Bennish and Mr. M.A. Wahed.

Summary of Referee's Opinions: Please see the following table to evaluate the various aspects of the proposal by checking the appropriate boxes. Your detailed comments are sought on a separate, attached page.

| | Rank Score | | |
|---------------------------------------|------------|--------|-----|
| | High | Medium | Low |
| Quality of Project | ✓ to ✓ | | |
| Adequacy of Project Design | ✓ | | |
| Suitability of Methodology | ✓ Mostly | | |
| Feasibility within time period | ✓ | | |
| Appropriateness of Budget | ✓ | | |
| Potential value to field of knowledge | ? | | |

CONCLUSIONS

I support the application:

- a) without qualification
- b) with qualification:
- on technical grounds
 - on level of financial support

Fairly minor. See overleaf

I do not support the application

Name of Referee: PROFESSOR P. C. WILKINSON

Position: Professor

Institution: Immunology Dept., University of Glasgow

Peter C. Wilkinson
Signature

31st August 1990
Date